Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-Outcomes: AZD0780 for Prevention of Major Adverse Cardiovascular Events
jRCT2031250199Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, atherosclerotic disease, arteriosclerosis obliterans and 5 more comparing AZD0780 with Placebo (2 arms). Primary endpoint: Time to first event of any component of MACE-PLUS. Started Jul 2025; status: recruiting.
02
Drugs
laroprovstat
03
Conditions
dyslipidemiaatherosclerotic diseasearteriosclerosis obliteransmyocardial infarction (MI)ischemic stroke
Beyond the preview
Go deeper on jRCT2031250199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250199.